Edgewise Reveals EDG-7500 Data Targeting Novel Cardiac Muscle Protein
Boulder, Colorado – September 22, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) disclosed preclinical data showing its lead cardiac drug candidate EDG-7500 improves heart relaxation while preserving systolic function, a mechanism the company says addresses a core driver of hypertrophic cardiomyopathy (HCM) that current therapies do not fully target.
Edgewise screened over 7,000 candidates to isolate a first-in-class RLC modulator
The company's Chief Scientific Officer, Alan Russell, said Edgewise screened more than 7,000 pharmacologically diverse compounds targeting the Regulatory Light Chain (RLC) before selecting molecules exhibiting positive lusitropic properties without compromising systolic performance. "EDG-7500's diastolic-biased profile has the potential to address a central pathologic driver of both symptomatic obstructive and nonobstructive HCM," Russell said.